Work

Economic value of Tislelizumab plus chemotherapy in advanced oesophageal squamous-cell carcinoma: a price-dependent analysis under uncertain comparator eligibility

Year: 2026
Type: article
Abstract: To estimate conditional break-even acquisition prices for tislelizumab plus chemotherapy against existing immunotherapy comparators in advanced oesophageal squamous-cell carcinoma, examining comparative efficacy, comparator acquisition discounts and relative treatment exposure.
Language: English
Open Access status: green
OpenAlex ID: W7236833406
FWCI:
Cites:
Cited by:
Related to: 10